Report of a participant of the XI Congress of the Russian Аssociation of Оncological Urology. Bladder cancer: what’s new in 2016

Bladder cancer (BC) remains one of the most common oncourological diseases. Five-year survival for patients with Т3–4N0M0 stage remains at the level of 33–52 %. Average life span for patients with metastases is 9–26 months. Changes in application of immediate adjuvant therapy for non-muscle invasive BC were made, as well as in selection of surgical treatment: open or laparoscopic cystectomy. Results of cystectomy depending on pathohistological tumor structure were studied. Lymph nodes were more frequently affected with urothelial cancer with squamous metaplasia. The role of the number of metastatic lymph nodes after radical cystectomy in determination of treatment strategy is still open for discussion. It was shown that even 1 metastatic lymph node reduces survival by 30 % and requires adjuvant chemotherapy. Blood transfusion during radical cystectomy negatively affects immune system functioning, increases frequency of infectious complications (sepsis, pneumonia, abscess). Metastasectomy performed in cases with positive response to chemotherapy can increase patients’ life span. Median survival was 35.4 months after lesion discovery and 34.3 months after metastasectomy. Efficiency and tolerability profiles for 2 chemotherapy regimens were studied: vinflunine + gemcitabine and vinflunine + carboplatin. Comparative analysis has shown that the regimes are equally effective, no significant differences were observed. New anti-tumor drugs for patients with metastatic BC are being actively researched. In 2016 the American Society of Clinical Oncology (ASCO) presented data on atezolizumab. The drug was injected intravenously at doses 1200 mg/m23 times a week. This regimen was effective both in a patient group receiving cisplatin and in a patient group untreated with this drug. In May of 2016 atezolizumab was registered by the Food and Drug Administration (FDA) for BC treatment on a priority basis. 

1. European Association of Urology. Guidelines 2016 edition. Guidelines on bladder cancer muscle-invasive and metastatic. P. 25, 27, 28, 45.

2. European Association of Urology. Guidelines 2016 edition. Guidelines on TaT1 (Non-muscle invasive) bladder cancer. P. 4, 27.

3. Aziz A., Bes P., Chun F.K. et al. Discrepancy between guidelines and daily practice in the management of non-muscleinvasive bladder center (NMIBC): results of a European survey. Eur Urol 2016;15 (3):e216.

4. Toshinori N., Aichi N., Toyonori T. et al. Measuring the depth of tumor invasion may have greater prognostic value than AJCC/ UICC staging of bladder cancer. AUA 2016;MP38–07.

5. Martini T., Gilfrich C., Mayr R. et al. The use of neoadjuvant chemotherapy in patients with urothelial carcinoma of the bladder: current practice among clinicians. Clin Genitourin Cancer 2016. DOI: 10.1016/j.clgc.2016.09.003. PMID: 27765613.

6. Vernez S.L., Abdelhalim A., Dutta R. et al. pathological characteristics and prognostic indicators of different histopathological types following radical cystectomy: a large cohort with long-term follow-up. AUA 2016; PD33–04.

7. Elsaadany M.M., Mansour A.M., El-Tabey N.A. et al. Singly lymph node malignant involvement radical cystectomy for urothelial carcinoma of the bladder: clinical outcomes and prognostic implications. AUA 2016;PD 33–12.

8. Fakhreldin I., Harraz A., Laymon M. et al. Urethral recurrence after radical cystectomy: revisiting the incidence and predictors in a large contemporary series. AUA 2016; МР 38–18.

9. Liu J.-J., Acevedo A.M., Amling C. Allogeneic blood transfusion increases infectious complications but not mortality after radical cystectomy. AUA 2016;МР 63–04.

10. Werntz R., Koppie T., Brian Junio B. et al. prophylactic antibiotics in the first 30 days following radical cystectomy with urinary diversion leads to fewer urinary tract infections. AUA 2016;МР 38–12.

11. Hosseini A., Collins J., Adding C. et al. Complications after totally intracorporeal robot-assisted radical cystectomy: results from the European association of urology Robotic Urology Section (ERUS) scientific working group. AUA 2016;PD 39–03.

12. Nakagawa T., Taguchi S., Kanatani A. et al. Outcome of metastasectomy for urothelial carcinoma: a multi-institutional retrospective study. AUA 2016;PD 33–01.

13. Tracey J., Ambani S., Osawa T. et al. Weekend discharge after radical cystectomy and the risk of readmission. AUA 2016; МP 63–17.

14. Волкова М.И., Черняев В.А., Матвеев В.Б. и др. Эффективность и безопасность винфлунина во 2-й линии терапии у больных переходно-клеточным раком мочевых путей в клинической практике. Онкоурология 2016;12(3):74–81. [Volkova M.I., Chernyaev V.A., Matveev V.B. et al. The efficacy and safety of vinflunine in second-line therapy of patients with disseminated transitional cell carcinoma of the urinary tract in clinical practice. Oncourologiya = Cancer Urology 2016;12(3):74–81. (In Russ.)].

15. Holmsten K., Dohn L., Jensen N.V. et al. Vinflunine treatment in patients with metastatic urorhelial cancer: a Nordic retrospective multicenter analysis. Oncol Lett 2016;12(2):1293–1300. DOI: 10.3892/ol.2016.4775. PMID: 27446429.

16. De Santis M., Wiechno P.J., Bellmunt J. Vinflunine-gemcitabine versus vinfluninecarboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1). Ann Oncol 2016;27(3):449–54. DOI: 10.1093/annonc/mdv609. PMID: 26673352.

17. Balar A.V., Galsky M.D., Loriot Y. et al. Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/ metastatic urothelial carcinoma (mUC): primary analysis of IMvigor210 cohort 1. ASCO Annual Meeting 2016;suppl. Abstr LBA4500.

18. Dreicer R., Hoffman-Censits J.H., Flaig T.W. Updated efficacy and > 1-y follow up from IMvigor210: Atezolizumab (atezo) in platinum (plat) treated locally advanced/ metastatic urothelial carcinoma (mUC). ASCO Annual Meeting 2016;suppl. Abstr LBA4515.